Pharmaceutical cocrystals and poorly soluble drugs

International Journal of Pharmaceutics

Volumn 453, Issue 1, 2013, Pages 101-125

  Thakuria, Ranjit ^a   Delori, Amit ^a   Jones, William ^a   Lipert, Maya P ^b   Roy, Lilly ^b   Rodríguez Hornedo, Naír ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cocrystals; Crystal engineering; Pharmaceutical cocrystallisation; Poorly soluble drugs; Solubility enhancement; Supramolecular chemistry

Indexed keywords

4 AMINOBENZOIC ACID DERIVATIVE; AMIDE; CAFFEINE; CARBAMAZEPINE; CELECOXIB; CHLORAL HYDRATE; CURCUMIN; ETHENZAMIDE; EXEMESTANE; FLUOXETINE; FUROSEMIDE; INDOMETACIN; INDOMETACIN DERIVATIVE; ITRACONAZOLE; LAMOTRIGINE; MEGESTROL ACETATE; MELOXICAM; N [4 [6 [4 (TRIFLUOROMETHYL)PHENYL] 4 PYRIMIDINYLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; NITROFURANTOIN; NORFLOXACIN; PIROXICAM; QUERCETIN; SALICYLIC ACID; TEMOZOLOMIDE; TRYPTAMINE;

CRYSTAL; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG STABILITY; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID STATE; SUPRAMOLECULAR CHEMISTRY; THERMODYNAMICS;

EID: 84884142576     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.10.043     Document Type: Review

References (163)

1. Aakeröy, C.B., Salmon, D.J., 2005. Building co-crystals with molecular sense and supramolecular sensibility. CrystEngComm 7, 439-448. (Pubitemid 41396867)
2. Aakeröy, C.B., Fasulo, M.E., Desper, J., 2007. Cocrystal or salt: does it really matter? Mol. Pharm. 3, 3177-3322.
3. Aakeröy, C.B., Rajbanshi, A., Li, Z.J., Desper, J., 2010. Mapping out the synthetic landscape for re-crystallization, co-crystallization and salt formation. CrystEngComm 12, 4231-4239.
4. Aakeröy, C.B., Forbes, S., Desper, J., 2009. Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug. J. Am. Chem. Soc. 131, 17048-17049.
5. Abdalla, A., Maeder, K., 2007. Preparation and characterization of a self-emulsifying pellet formulation. Eur. J. Pharm. Biopharm. 66, 220-226. (Pubitemid 46654779)
6. Abramov, Y.A., Loschen, C., Klant, A., 2012. Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation. J. Pharm. Sci. 101, 3697.
7. Aitipamula, S., Chow, P.S., Tan, R.B.H., 2009a. Dimorphs of a 1:1 cocrystal of ethenzamide and saccharin: solid-state grinding methods result in metastable polymorph. CrystEngComm 11, 889-895.
8. Aitipamula, S., Chow, P.S., Tan, R.B.H., 2009b. Trimorphs of a pharmaceutical cocrystal involving two active pharmaceutical ingredients: potential relevance to combination drugs. CrystEngComm 11, 1823-1827.
9. Aitipamula, S., Chow, P.S., Tan, R.B.H., 2010a. Conformational and enantiotropic polymorphism of a 1:1 cocrystal involving ethenzamide and ethylmalonic acid. CrystEngComm 12, 3691-3697.
10. Aitipamula, S., Chow, P.S., Tan, R.B.H., 2010b. Polymorphs and solvates of a cocrystal involving an analgesic drug, ethenzamide, and 3,5-dinitrobenzoic acid. Cryst. Growth Des. 10, 2229-2238.
11. Aitipamula, S., et al., 2012. Polymorphs, salts and cocrystals: what's in a name? Cryst. Growth Des. 12, 2147-2152.
12. Alhalaweh, A., Sokolowski, A., Rodríguez-Hornedo, N., Velaga, S.P., 2011. Solubility behavior and solution chemistry of indomethacin cocrystals in organic solvents. Cryst. Growth Des. 11, 3923-3929.
13. Alhalaweh, A., Roy, L., Rodriguez-Hornedo, N., Velaga, S.P., 2012. pH-dependent solubility of indomethacin-saccharin and carbamzapine-saccahrine cocrystals in aqueous media. Mol. Pharm. 9, 2605-2612.
14. Almarsson, O., Zaworotko, M.J., 2004. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem. Commun., 1889-1896. (Pubitemid 39335992)
15. Anderson, B.D., Conradi, R.A., 1985. Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J. Pharm. Sci. 74, 815-820. (Pubitemid 15042168)
16. Avdeef, A., 2007. Solubility of sparingly-soluble ionizable drugs. Adv. Drug Deliv. Rev. 59, 568-590. (Pubitemid 47285405)
17. Babu, N.J., Nangia, N., 2011. Solubility advantage of amorphous drugs and pharmaceutical cocrystals. Cryst. Growth Des. 11, 2662-2679.
18. Babu, N.J., Reddy, L.S., Aitipamula, S., Nangia, A., 2008. Polymorphs and polymorphic cocrystals of temozolomide. Chem. Asian J. 3, 1122-1133.
19. Bag, P.P., Reddy, C.M., 2012. Screening and selective prepartion of polymorphs by fast evaporation methods: a case study of aspirin, antranilic acid and niflumic acid. Cryst. Growth Des. 12, 2740-2743.
20. Bag, P.P., Patni, M., Reddy, C.M., 2011. A kinetically controlled crystallization process for identifying new co-crystal forms: fast evaporation of solvent from solutions to dryness. CrystEngComm 13, 5650-5652.
21. Bak, A., Gore, A., Yanez, E., Stanton, M., Tufekcic, S., Syed, R., Akrami, A., Rose, M., Surapaneni, S., Bostick, T., King, A., Neervannan, S., Ostovic, D., Koparkar, A., 2008. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J. Pharm. Sci. 97, 3942-3956.
22. Banerjee, R., Bhatt, P.M., Ravindra, N.V., Desiraju, G.R., 2005. Saccharin salts of active pharmaceutical ingredients, their crystal structures, and increased water solubilities. Cryst. Growth Des. 5, 2299-2309. (Pubitemid 41619324)
23. Barbas, R., Marti, F., Prohens, R., Puigjaner, C., 2006. Polymorphism of norfloxacin: evidence of the enantiotropic relationship between polymorphs A and B. Cryst. Growth Des. 6, 1463-1467. (Pubitemid 44000229)
24. Barbas, R., Prohens, R., Puigjaner, C., 2007. A new polymorph of norfloxacin. Complete characterization and relative stability of its trimorphic system. J. Therm. Anal. Calorim. 89, 687-692. (Pubitemid 47351759)
25. Bardwell, D.A., et al., 2011. Towards crystal structure prediction of complex organic compounds - a report of the fifth blind test. Acta Cryst. B67, 535-551.
26. Basavoju, S., Boström, D., Velaga, S.P., 2006. Pharmaceutical cocrystal and salts of norfloxacin. Cryst. Growth Des. 6, 2699-2708.
27. Basavoju, S., Boström, D., Velaga, S.P., 2008. Indomethacin- saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization. Pharm. Res. 25, 530-541. (Pubitemid 351357724)
28. Bauer, J., Spanton, S., Henry, R., Quick, J., Dziki, W., Porter, W., Morris, J., 2001. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 18, 859-866. (Pubitemid 32783524)
29. Berge, S.M., Bighley, L.D., Monkhouse, D.C., 1977. Pharmaceutical salts. J. Pharm. Sci. 66, 1-19.
30. Berry, D.J., Seaton, C.C., Clegg, W., Harrington, R.W., Coles, S.J., Horton, P.N., Hursthouse, M.B., Storey, R., Jones, W., Frišč ić, T., Blagden, N., 2008. Applying hot-stage microscopy to co-crystal screening: a study of nicotinamide with seven active pharmaceutical ingredients. Cryst. Growth Des. 8, 1697-1712.
31. Bethune, S.J., Huang, N., Jayasankar, A., Rodríguez-Hornedo, 2009. Understanding and predicting the effect of cocrystal components and pH on cocrystal solubility. Cryst. Growth Des., 3976-3988.
32. Bethune, S.J., Schultheiss, N., Henck, J.-O., 2011. Improving the poor aqueous solubility of nutraceutical compound pterostilbene through cocrystal formation. Cryst. Growth Des. 11, 2817-2823.
33. Bhatt, P.M., Ravindra, N.V., Banerjee, R., Desiraju, G.R., 2005. Saccharin as a salt former. Enhanced solubilities of saccharinates of active pharmaceutical ingredients. Chem. Commun., 1073-1075. (Pubitemid 40363476)
34. Bhogala, B.R., Nangia, A., 2008. Ternary and quaternary co-crystals of 1,3-cis,5-cis-cyclohexanetricarboxylic acid and 4,4′-bipyridines. New J. Chem. 32, 800-807. (Pubitemid 351668109)
35. Bhogala, B.R., Basavoju, S., Nangia, A., 2005. Tape and layer structures in cocrystals of some di- and tricarboxylic acids with 4,4′-bipyridines and isonicotinamide. From binary to ternary cocrystals. CrystEngComm 7, 551-562. (Pubitemid 41396850)
36. Birdi, K.S., 2003. Handbook of Surface and Colloid Chemistry. CRC Press, Boca Raton, FL.
37. Blagden, N., de Matas, M., Gavan, P.T., York, P., 2007. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv. Drug Deliv. Rev. 59, 617-630. (Pubitemid 47285407)
38. Bond, A.D., 2006. Inversion of the melting point alternation in n-alkyl carboxylic acids by co-crystallisation with pyrazine. CrystEngComm 8, 333-337. (Pubitemid 43673664)
39. Braga, D., Giaffreda, S.L., Grepioni, F., Chierotti, M.R., Gobetto, R., Palladino, G., Polito, M., 2007. Solvent effect in a "solvent free" reaction. CrystEngComm 9, 879-881.
40. Brower, V., 1998. Nutraceuticals: poised for a healthy slice of the healthcare market? Nat. Biotechnol. 7, 728-731.
41. Caira, M.R., Pienaar, E.W., Loetter, A.P., 1996. Polymorphism and pseudopolymorphism of the antibacterial nitrofurantoin. Mol. Cryst. Liq. Cryst. Sci. Technol. Sect. A 279, 241-264. (Pubitemid 126577678)
42. Caruso, F., Tanski, J., Villegas-Estrada, A., Rossi, M., 2004. Structural basis for antioxidant activity of trans-resveratrol: ab initio calculations and crystal and molecular structure. J. Agric. Food Chem. 52, 7279-7285.
43. Chadha, R., Saini, A., Arora, P., Jain, D.S., Dasgupta, A., Row, T.N.G., 2011. Multicomponent solids of lamotrigine with some selected coformers and their characterization by thermoanalytical, spectroscopic and X-ray diffraction methods. CrystEngComm 13, 6271-6284.
44. Chawla, G., Gupta, P., Thilagavathi, R., Chakraborti, A.K., Bansal, A.K., 2003. Characterization of solid-state forms of celecoxib. Eur. J. Pharm. Sci. 20, 305-317. (Pubitemid 37338536)
45. Cheney, M.L., Shan, N., Healey, E.R., Hanna, M., Wojtas, L., Zaworotko, M.J., Sava, V., Song, S.J., Sanchez-Ramos, J.R., 2010a. Effects of crystal form on solubility and pharmacokinetics: a crystal engineering case study of lamotrigine. Cryst. Growth Des. 10, 394-405.
46. Cheney, M.L., Weyna, D.R., Shan, N., Hanna, M., Wojtas, L., Zaworotko, M.J., 2010b. Supramolecular architectures of meloxicam carboxylic acid cocrystals, a crystal engineering case study. Cryst. Growth Des. 10, 4401-4413.
47. Cheney, M.L., Weyna, D.R., Shan, N., Hanna, M., Wojtas, L., Zaworotko, M.J., 2011. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. J. Pharm. Sci. 100, 2172-2181.
48. Cherukuvada, S., Babu, N.J., Nangia, A., 2011. Nitrofurantoin-p- aminobenzoic acid cocrystal: hydration stability and dissolution rate studies. J. Pharm. Sci. 100, 3233-3244.
49. Chiarella, R.A., Davey, R.J., Peterson, M.L., 2007. Making co-crystals - the utility of ternary phase diagrams. Cryst. Growth Des. 7, 1223-1226.
50. Childs, S.L., Hardcastle, K.I., 2007. Cocrystals of piroxicam with carboxylic acids. Cryst. Growth Des. 7, 1291-1304.
51. Childs, S.L., Chyall, L.J., Dunlap, J.T., Smolenskaya, V.N., Stahly, B.C., Stahly, G.P., 2004. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J. Am. Chem. Soc. 126, 13335-13342. (Pubitemid 39382761)
52. Childs, S.L., Stahly, G.P., Park, A., 2007. The salt-cocrystal continuum: the influence of crystal structure on ionisation state. Mol. Pharm. 4, 323-338. (Pubitemid 46983949)
53. Childs, S.L., Rodríguez-Hornedo, N., Reddy, L.S., Jayasankar, A., Maheshwari, C., McCausland, L., Shipplett, R., Stahly, B.C., 2008. Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. CrystEngComm 10, 856-864.
54. Childs, S.L., Wood, P.A., Rodríguez-Hornedo, N., Reddy, L.S., Hardcastle, K.I., 2009. Analysis of 50 crystal structures containing carbamazepine using the materials module of mercury CSD. Cryst. Growth Des. 9, 1869-1888.
55. Chongcharoen, W., Byrn, S.R., Sutanthavibul, N., 2008. Solid state interconversion between anhydrous norfloxacin and its hydrates. J. Pharm. Sci. 97, 473-489.
56. Christian, S.D., Scamehorn, J.F., 1995. Solubilization in Surfactant Aggregates. Marcel Dekker, New York, NY.
57. Delori, A., Suresh, E., Pedireddi, V.R., 2008. pKa-directed host-guest assemblies: rational analysis of molecular adducts of 2,4-diamino-6-methyl-1,3, 5-triazine with various aliphatic dicarboxylic acids. Chem. Eur. J. 14, 6967-6977.
58. Delori, A., Friščić, T., Jones, W., 2012a. The role of mechanochemistry and supramolecular design in the development of pharmaceutical materials. CrystEngComm 14, 2350-2362.
59. Delori, A., Galek, P.T.A., Pidcock, E., Jones, W., 2012b. Quantifying homo- and heteromolecular hydrogen bonds as a guide for adduct formation. Chem. Eur. J. 18, 6835-6846.
60. Delori, A., Galek, P.T.A., Pidcock, E., Patni, M., Jones W, 2013. Knowledge-based hydrogen bond prediction and the synthesis of salts and cocrystals of the anti-malarial drug pyrimethamine with various drug and GRAS molecules. CrystEngComm, http://dx.doi.org/10.1039/c3ce26765b.
61. Desiraju, G.R., 1995. Supramolecular synthons in crystal engineering - a new organic synthesis. Angew. Chem. Int. Ed. Engl. 34, 2311-2327.
62. Dhumal, R.S., Kelly, A.L., York, P., Coates, P.D., Paradkar, A., 2010. Cocrystallization and simultaneous agglomeration using hot melt extrusion. Pharm. Res. 27, 2725-2733.
63. Fábián, L., 2009. Cambridge structural database analysis of molecular complementarity in cocrystals. Cryst. Growth Des. 9, 1436-1443.
64. Fahr, A., Liu, X., 2007. Drug delivery strategies for poorly water-soluble drugs. Expert Opin. Drug Deliv. 4, 403-416. (Pubitemid 47249138)
65. Fayos, J., 2009. Molecular crystal prediction approach by molecular similarity: data mining on molecular aggregation predictors and crystal descriptors. Cryst. Growth Des. 9, 3142-3153.
66. FDA, 2011. Guidance for Industry. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidance1054s/UCM281764.pdf
67. Fleischman, S.G., Kuduva, S.S., McMahon, J.A., Moulton, B., Bailey Walsh, R.D., Rodríguez-Hornedo, N., Zaworotko, M.J., 2003. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. Cryst. Growth Des. 3, 909-919. (Pubitemid 37474229)
68. Florence, A.T., Attwood, D., 2006. Physicochemical Principles of Pharmacy, fourth ed. Pharamceutical Press, London, UK.
69. Florence, A.J., Kennedy, A.R., Shankland, N., Wright, E., Al-Rubayi, A., 2000. Norfloxacin dihydrate. Acta Crystallogr. Sect. C: Cryst. Struct. Commun. C56, 1372-1373. (Pubitemid 32025168)
70. Florence, A.J., Johnston, A., Price, S.L., Nowell, H., Kennedy, A.R., Shankland, N., 2006. An automated parallel crystallization search for predicted crystal structures and packing motifs of carbamazepine. J. Pharm. Sci. 95, 1918-1930. (Pubitemid 44433024)
71. Friščić, T., Jones, W., 2010. Benefits of cocrystallisation in pharmaceutical materials science: an update. J. Pharm. Pharmacol. 62, 1547-1559.
72. Galcera, J., Molins, E., 2009. Effect of the counterion on the solubility of isostructural pharmaceutical lamotrigine salts. Cryst. Growth Des. 9, 327-334.
73. Galek, P.T.A., Fábián, L., Motherwell, W.D.S., Allen, F.H., Feeder, N., 2007. Knowledge-based model of hydrogen-bonding propensity in organic crystals. Acta Cryst. B63, 768-782. (Pubitemid 47460163)
74. Good, D.J., 2010. Pharmaceutical Cocrystal Eutectic Analysis: Study of Thermodynamic Stability, Solubility, and Phase Behavior. Ph.D. Thesis, University of Michigan, Ann Arbor, MI.
75. Good, D.J., Rodríguez-Hornedo, N., 2009. Solubility advantage of pharmaceutical cocrystals. Cryst. Growth Des. 9, 2252-2264.
76. Good, D.J., Rodríguez-Hornedo, N., 2010. Cocrystal eutectic constants and prediction of solubility behavior. Cryst. Growth Des. 10, 1028-1032.
77. Good, D.J., Miranda, C., Rodríguez-Hornedo, N., 2011. Dependence of cocrystal formation and thermodynamic stability on moisture sorption by amorphous polymer. CrystEngComm 1, 1181-1189.
78. Goud, N.R., Gangavaram, S., Suresh, K., Pal, S., Manjunatha, S.G., Nambiar, S., Nangia, A., 2012. Novel furosemide cocrystals and selection of high solubility drug forms. J. Pharm. Sci. 101, 664-680.
79. Grant, D.J.W., Higuchi, T., 1990. Solubility Behavior of Organic Compounds. Wiley, New York, NY.
80. Grzesiak, A.L., Lang, M., Kim, K., Matzger, A.J., 2003. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J. Pharm. Sci. 92, 2260-2271. (Pubitemid 37356699)
81. Guzmán, H.R., Tawa, M., Zhang, Z., Ratanabanangkoon, P., Shaw, P., Gardner, C.R., Chen, H., Moreau, J.P., Almarsson, Ö., Remenar, J.F., 2007. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 96, 2686-2702. (Pubitemid 47597818)
82. Habgood, M., Deij, M.A., Mazurek, J., Price, S.L., ter Horst, J.H., 2010. Carbamazepine co-crystallization with pyridine carboxamides: rationalization by complementary phase diagrams and crystal energy landscapes. Cryst. Growth Des. 10, 903-912.
83. Hancock, B.C., Zografi, G., 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86, 1-12.
84. Harris, R.K., Ghi, P.Y., Puschmann, H., Apperley, D.C., Griesser, U.J., Hammond, R.B., Ma, C., Roberts, K.J., Pearce, G.J., Yates, J.R., Pickard, C.J., 2005. Structural studies of the polymorphs of carbamazepine, its dihydrate, and two solvates. Org. Process Res. Dev. 9, 902-910. (Pubitemid 41784114)
85. Hecq, J., Deleers, M., Fanara, D., Vranckx, H., Amighi, K., 2005. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299, 167-177. (Pubitemid 40962418)
86. Hickey, M.B., Peterson, M.L., Scoppettuolo, L.A., Morrisette, S.L., Vetter, A., Guzman, H., Remenar, J.F., Zhang, Z., Tawa, M.D., Haley, S., Zaworotko, M.J., Almarsson, O., 2007. Performance comparison of a co-crystal of carbamazepine with marketed product. Eur. J. Pharm. Biopharm. 67, 112-119. (Pubitemid 46991320)
87. Hildebrand, J.H., 1924. Solubility. The Chemical Catalog Company, Inc., New York, New York, USA.
88. Hildebrand, J.H., Scott, R.L., 1950. The Solubility of Nonelectrolytes. Reinhold Publishing, New York, New York, USA.
89. Hu, T.-C., Wang, S-L., Chen, T-F., Lin, S-Y., 2002. Hydration-induced proton transfer in the solid state of norfloxacin. J. Pharm. Sci. 91, 1351-1357. (Pubitemid 34651197)
90. Huang, N., Rodríguez-Hornedo, N., 2010. Effect of micellar solubilization on cocrystal solubility and stability. Cryst. Growth Des., 2050-2053.
91. Huang, N., Rodríguez-Hornedo, N., 2011. Engineering cocrystal thermodynamic stability and eutectic points by micellar solubilization and ionization. CrystEngComm, 5409-5422.
92. Issa, N., Karamertzanis, P.G., Welch, G.W.A., Price, S.L., 2009. Can the formation of pharmaceutical cocrystals be computationally predicted? I. Comparison of lattice energies. Cryst. Growth Des. 4, 442-453.
93. James, S.L., Adams, C.J., Bolm, C., Braga, D., Collier, P., Friščić, T., Grepioni, F., Harris, K.D.M., Hyett, G., Jones, W., Krebs, A., Mack, J., Maini, L., Orpen, A.G., Parkin, I.P., Shearouse, W.C., Steed, J.W., Waddell, D.C., 2012. Mechanochemistry: opportunities for new and cleaner synthesis. Chem. Soc. Rev. 41, 413-447.
94. Jayasankar, A., Somwangthanaroj, A., Shao, Z.J., Rodríguez- Hornedo, N., 2006. Cocrystal formation during cogrinding and storage is mediated by amorphous phase. Pharm. Res. 23, 2381-2392. (Pubitemid 44511518)
95. Jayasankar, A., Good, D.J., Rodríguez-Hornedo, N., 2007. Mechanisms by which moisture generates cocrystals. Mol. Pharm. 4, 360-372. (Pubitemid 46983953)
96. Jayasankar, A., Reddy, L.S., Bethune, S.J., Rodriguez-Hornedo, N., 2009. Role of Cocrystal and Solution Chemistry on the Formation and Stability of Cocrystals with Different Stoichiometry. Cryst. Growth Des. 9, 889-897.
97. Jayasankar, A., Roy, L., Rodríguez-Hornedo, N., 2010. Transformation pathways of cocrystal hydrates. J. Pharm. Sci., 3977-3985.
98. Johnston, A., Johnston, B.F., Kennedy, A.R., Florence, A.J., 2008. Targeted crystallisation of novel carbamazepine solvates based on a retrospective random forest classification. CrystEngComm 10, 23-25.
99. Jones, W., Motherwell, W.D.S., Trask, A.V., 2006. Pharmaceutical cocrystals: an emerging approach to physical property enhancement. MRS Bull. 31, 875-879. (Pubitemid 44826643)
100. Jung, M-S., Kim, J-S., Kim, M-S., Alhalaweh, A., Cho, W., Hwang, S-J., Velaga, S.P., 2010. Bioavailability of indomethacin-saccharin cocrystals. J. Pharm. Pharmacol. 62, 1560-1568.
101. Kobayashi, Y., Ito, S., Itai, S., Yamamoto, K., 2000. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 193, 137-146. (Pubitemid 30001856)
102. Koshima, H., Miyauchi, M., 2001. Polymorphs of a cocrystal with achiral and chiral structures prepared by pseudoseeding: tryptamine/hydrocinnamic acid. Cryst. Growth Des. 1, 355-357. (Pubitemid 33717099)
103. Leuner, C., Dressman, J., 2000. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50, 47-60. (Pubitemid 30326688)
104. Liu, R., 2008. Water-insoluble Drug Formulation. CRC Press, Boca Raton, FL.
105. Lu, G.W., Hawley, M., Smith, M., Geiger, B.M., Pfund, W., 2006. Characterisation of a novel polymorphic form of celecoxib. J. Pharm. Sci. 95, 305-317. (Pubitemid 43241973)
106. Lu, E., Rodríguez-Hornedo, N., Suryanarayanan, R., 2008. A rapid thermal method for cocrystal screening. CrystEngComm 10, 665-668.
107. Maheshwari, C., André, V., Reddy, L.S., Roy, L., Duarte, T., Rodríguez-Hornedo, N., 2012. Tailoring aqueous solubility of a highly soluble compound via cocrystallization: effect of coformer ionization, pHmax, and solute-solvent interactions. CrystEngComm, 4801-4811.
108. McMahon, J.A., Bis, J.A., Vishweshwar, P., Shattock, T.R., McLaughlin, O.L., Zaworotko, M.J., 2005. Crystal engineering of the composition of pharmaceutical phases. 3. Primary amide supramolecular heterosynthons and their role in the design of pharmaceutical co-crystals. Z. Kristallogr. 220, 340-350. (Pubitemid 40515882)
109. McNamara, D.P., Childs, S.L., Giordano, J., Iarriccio, A., Cassidy, J., Shet, M.S., Mannion, R., O'Donnell, E., Park, A., 2006. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm. Res. 23, 1888-1897. (Pubitemid 44200553)
110. Meanwell, N.A., 2008. The emerging utility of co-crystals in drug discovery and development. Annu. Rep. Med. Chem. 43, 373-404.
111. Miyako, Y., Tai, H., Ikeda, K., Kume, R., Pinal, R., 2008. Solubility screening on a series of structurally related compounds: cosolvent-induced changes on the activity coefficient of hydrophobic solutes. Drug Dev. Ind., 499-505.
112. Murdande, S.B., Pikal, M.J., Shanker, R.M., Bogner, R.H., 2010. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis. J. Pharm. Sci. 99, 1254-1264.
113. Musumeci, D., Hunter, C.A., Prohens, R., Scuderi, S., McCabe, J.F., 2011. Virtual cocrystal screening. Chem. Sci., 883-890.
114. Myers, D., 1992. Surfactant Science and Technology. Wiley-VCH, New York, NY.
115. Nehm, S.J., Rodriguez-Spong, B., Rodriguez-Hornedo, N., 2006. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst. Growth Des. 6, 592-600. (Pubitemid 43242126)
116. Paulson, S.K., Vaughn, M.B., Jessen, S.M., Lawal, Y., Gresk, C.J., Yan, B., Maziasz, T.J., Cook, C.S., Karim, A., 2001. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J. Pharmacol. Exp. Ther. 297, 638-645. (Pubitemid 32377995)
117. Pienaar, E.W., Caira, M.R., Lotter, A.P., 1993. Polymorphs of nitrofurantoin. I. Preparation and X-ray crystal structures of two monohydrated forms of nitrofurantoin. J. Crystallogr. Spectrosc. Res. 23, 739-744.
118. Pienaar, E.W., Caira, M.R., Lotter, A.P., 1992. Polymorphs of nitrofurantoin. 2. Preparation and X-ray crystal structures of two anhydrous forms of nitrofurantoin. J. Cryst. Spectrosc. Res. 10, 785-790.
119. Porter, W.W., Elie, S.C., Matzger, A.J., 2008. Polymorphism in carbamazepine cocrystals. Cryst. Growth Des. 8, 14-16.
120. Pudipeddi, M., Serajuddin, A.T.M., 2005. Trends in solubility of polymorphs. J. Pharm. Sci. 94, 929-939. (Pubitemid 40780760)
121. Pudipeddi, M., Serajuddin, A.T.M., Grant, D.J.W., Stahl, P.H., 2002. Solubility and dissolution of weak acids, bases, and salts. In: Stahl, P.H., Wermuth, G. (Eds.), Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Wiley-VCH, New York, NY.
122. Puigjaner, C., Barbas, R., Portell, A., Font-Bardia, M., Alcobe, X., Prohens, R., 2010. Revisiting the solid state of norfloxacin. Cryst. Growth Des. 10, 2948-2953.
123. Puri, V., Dantuluri, A.K., Bansal, A.K., 2011. Investigation of atypical dissolution behavior of an encapsulated amorphous solid dispersion. J. Pharm. Sci. 100, 2460-2468.
124. Qiao, N., Li, M., Schlindwein, W., Malek, N., Davies, A., Trappitt, G., 2011. Pharmaceutical cocrystals: an overview. Int. J. Pharm. 419, 1-11.
125. Qiu, T., Chen, Y., Zhang, G.G.Z. (Eds.), 2009. Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice. Academic Press, Burlington, MA, USA.
126. Ravindra, N.V., Panpalia, G.M., Jagarlapudi, A.R.P.S., 2009. Norfloxacin sesquihydrate. Acta Crystallogr. Sect. E Struct. Rep. Online E65, o303.
127. Reddy, L.S., Bethune, S.J., Kampf, J.W., Rodríguez-Hornedo, N., 2009. Cocrystals and salts of gabapentin: pH dependent cocrystal stability and solubility. Cryst. Growth Des., 378-385.
128. Rele, S.M., 2008. Editorial. New Paradigms in Drug Formulation and Phytotherapeutics. In: Curr. Bioact. Compd. 4, 200.
129. Remenar, J.F., Morissette, S.L., Peterson, M.L., Moulton, B., MacPhee, J.M., Guzmán, H.R., Almarsson, Ö., 2003. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J. Am. Chem. Soc. 125, 8456-8457. (Pubitemid 36858412)
130. Remenar, J.F., Peterson, M.L., Stephens, P.W., Zhang, Z., Zimenkov, Y., Hickey, M.B., 2007. Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential. Mol. Pharm. 4, 386-400. (Pubitemid 46983955)
131. Remenar, J.F., Tawa, M.D., Peterson, M.L., Almarsson, O., Hickey, M.B., Foxman, B.M., 2011. Celoxib sodium salt: engineering crystal forms for performance. CrystEngComm 13, 1081-1089.
132. Robertson, D.W., Jones, N.D., Swartzendruber, J.K., Yang, K.S., Wong, D.T., 1988. Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor. J. Med. Chem. 31, 185-189. (Pubitemid 18027872)
133. Rodríguez-Hornedo, N., Nehm, S.J., Seefdelt, K.F., Pagan-Torres, Y., Falkiewicz, C.J., 2006. Reaction crystallization of pharmaceutical molecular complexes. Mol. Pharm. 3, 363-367.
134. Ross, D.L., Riley, C.M., 1990. Aqueous solubilities of some variously substituted quinolone antimicrobials. Int. J. Pharm. 63, 237-250.
135. Roy, S., Goud, N.R., Babu, N.J., Iqbal, J., Kruthiventi, A.K., Nangia, A., 2008. Crystal structures of norfloxacin hydrates. Cryst. Growth Des. 8, 4343-4346.
136. Sander, J.R.G., Bucar, D.-K., Henry, R.F., Zhang, G.G.Z., MacGillivray, L.R., 2010. Pharmaceutical nano-cocrystals: sonochemical synthesis by solvent selection and use of a surfactant. Angew. Chem. Int. Ed. Engl. 49, 7284-7288.
137. Sanphui, P., Goud, N.R., Khandavilli, U.B.R., Nangia, A., 2011. Fast dissolving curcumin cocrystals. Cryst. Growth Des. 11, 4135-4145.
138. Schultheiss, N., Newman, A., 2009. Pharmaceutical cocrystals and their physicochemical properties. Cryst. Growth Des. 9, 2950-2967.
139. Schultheiss, N., Bethune, S., Henck, J.-O., 2010. Nutraceutical cocrystals: utilizing pterostilbene as a cocrystal former. CrystEngComm 12, 2436-2442.
140. Schultheiss, N., Roe, M., Boerrigter, S.X.M., 2011. Cocrystals of nutraceutical p-coumaric acid with caffeine and theophylline: polymorphism and solid-state stability explored in detail using their crystal graphs. CrystEngComm 13, 611-619.
141. Serajuddin, A.T.M., 2007. Salt Formation to Improve Drug Solubility. Adv. Drug Delivery Rev., 603-616. (Pubitemid 47285406)
142. Shan, N., Zaworotko, M.J., 2008. The role of cocrystals in pharmaceutical science. Drug Discov. Today 13, 440-446.
143. Shan, N., Toda, F., Jones, W., 2002. Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics. Chem. Commun., 2372-2373. (Pubitemid 35283628)
144. Shiraki, K., Takata, N., Takano, R., Hayashi, Y., Terada, K., 2008. Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds. Pharm. Res. 25, 2581-2592.
145. Smith, A.J., Kavuru, P., Wojtas, L., Zaworotko, M.J., Shytle, R.D., 2011. Cocrystals of quercetin with improved solubility and oral bioavailability. Mol. Pharmaceut. 8, 1867-1876.
146. Stahl, P.H., Wermuth, C.G., 2002. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Wiley-VCH, New York, New York, USA.
147. Stahly, G.P., 2009. A survey of cocrystals reported prior to 2000. Cryst. Growth Des. 9, 4212-4229.
148. Stanton, M.K., Bak, A., 2008. Physicochemical properties of pharmaceutical cocrystals: A case study of ten AMG 517 co-crystals. Cryst. Growth Des. 8, 3856-3862.
149. Strickley, R.G., 2004. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 1, 201-230. (Pubitemid 38221966)
150. ter Horst, J.H., Cains, P.W., 2008. Co-crystal polymorphs from a solvent-mediated transformation. Cryst. Growth Des. 8, 2537-2542.
151. Thakuria, R., Nangia, A., 2011. Highly soluble olanzapinium maleate crystalline salts. CrystEngComm 13, 1759-1764.
152. Trask, A.V., Motherwell, W.D.S., Jones, W., 2004. Solvent-drop grinding: green polymorph control of cocrystallisation. Chem. Commun., 890-891. (Pubitemid 38530287)
153. Trask, A.V., Motherwell, W.D.S., Jones, W., 2005a. Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration. Cryst. Growth Des. 5, 1013-1021. (Pubitemid 40755572)
154. Trask, A.V., van de Streek, J., Motherwell, W.D.S., Jones, W., 2005b. Achieving polymorphic and stoichiometric diveristy in cocrystal formation: Importance of solid-state grinding, powder X-ray structure dtermination, and seeding. Cryst. Growth Des. 5, 2233-2241. (Pubitemid 41619316)
155. Tutughamiarso, M., Bolte, M., Wagnera, G., Egerta, G., 2011. Five pseudopolymorphs and a cocrystal of nitrofurantoin. Acta Cryst. C67, o18-o025.
156. Uekama, K., Hirayama, F., Irie, T., 1998. Cyclodextrin drug carrier systems. Chem. Rev. 98, 2045-2076. (Pubitemid 128633447)
157. Vishweshwar, P., Nangia, A., Lynch, V.M., 2003. Molecular complexes of homologous alkanedicarboxylic acids with isonicotinamide: X-ray crystal structures, hydrogen bond synthons, and melting point alternation. Cryst. Growth Des. 3, 783-790. (Pubitemid 37162291)
158. Vishweshwar, P., McMahon, J.A., Bis, J.A., Zaworotko, M.J., 2006. Pharmaceutical cocrystals. J. Pharm. Sci. 95, 499-516.
159. Weyna, D.R., Shattock, T.S., Vshweshwar, P., Zaworotko MJ, 2009. Synthesis and structural charactersiation of cocrystals and pharmaceutical cocrystals: mechanochemistry vs slow evaporation from solution. Cryst. Growth Des. 9, 1106-1123.
160. Weyna, D.R., Cheny, M.L., Shan, N., Hanna, M., Zaworotko, M.J., Sava, V., Song, S., Sanchez-Ramos, J.R., 2012. Improving solubility and pharmokinetics of meloxicam via multiple-component crystal formation. Mol. Pharmaceut. 9, 2094-2102.
161. Yadav, A.V., Dabke, A.P., Shete, A.S., 2010. Crystal Engineering to Improve Physicochemical Properties of Mefloquine Hydrochloride. Drug Dev. Ind. Pharm., 1036-1045.
162. Yalkowsky, S.H., 1999. Solubility and Solubilization in Aqueous Media. American Chemical Society, Oxford University Press, New York, USA.
163. Yu, L., 2001. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 48, 27-42. (Pubitemid 32454482)